Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement

Phlebology

Volumn 17, Issue 3-4, 2002, Pages 126-133

  Caprini, Joseph A ^b   Arcelus, J I ^a   Kudrna, J C ^c   Sehgal, L R ^c   Oyslender, M ^c   Maksimovic, D ^c   MacDougall, A ^c  

^a Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^c NONE

Author keywords

Cost effectiveness; Duplex ultrasound; Low molecular weight heparin; Total hip arthroplasty; Venography; Venous thromboembolism (VTE)

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; BLEEDING; COMPRESSION THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

EID: 0036971795     PISSN: 02683555     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02638605     Document Type: Article

References (33)

1. Bergqvist D, Mätzsch T, Jendteg S, Lindgren B, Persson U. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand 1990;156 (Suppl 556):341.
2. Colditz GA. Cost effectiveness of prevention. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH, editors. Prevention of venous thromboembolism. London: Med-Orion, 1994:405-20.
3. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987;257:203-8.
4. Anderson F, Hirsh J, White K. Temporal trends in practices in prevention of venous thromboembolism following primary total hip or knee arthroplasty: findings from the hip and knee registry. Thromb Haemost 2001;Supplement (CD):abstract P2258.
5. Gross M, Anderson DR. Nagpal S, O'Brien B. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg 1999;42:457-61.
6. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-12.
7. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and LMWH for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81:1742-6.
8. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of LMWH versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm 1997;54:1185-90.
9. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of LMWH vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
10. Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. Arch Intern Med 1997;157:298-303.
11. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of LMWH versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;150:1083-90.
12. Weinstein M, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
13. Siegel JE, Weinstein MC, Russell LB. Marthe RG. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-41.
14. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. User's guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice: A. Are the results of the study valid? JAMA 1997;277:1552-7.
15. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119:S132-75.
16. Levine MN, Hirsh J, Gent M. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-51.
17. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
18. RD heparin arthroplasty group. RD heparin compared with warfarin for prevention of venous thromboembolism disease following total hip or knee arthroplasty. J Bone Surg Am 1994;76:1174-84.
19. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, et al. Efficacy and safety of LMWH to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-9.
20. Colwell CW, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, et al. Use of LMWH, a low-molecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg Am 1994;76:3-14.
21. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular-weight heparin (LMWH) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
22. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of LMWH versus placebo. Lancet 1996;348:224-8.
23. Francis CW RJ, Evarts CM, Marder VJ. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty (abstract). Clin Orthop 1988;232:271-8.
24. Lavender R, Sung J, Nix L, Le D, McLaren S, Barnes R, et al. Efficacy of LMWH versus warfarin in DVT prevention as assessed by duplex scanning in post hip and knee arthroplasty patients. Thromb Haemost 2001;Suppl (CD):abstract P2312.
25. Suomalainen O, Mäkelä AE, Harju A, Jaroma H. Prevention of fatal pulmonary embolism with warfarin after total hip replacement. Int Orthop 1996;20:75-9.
26. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with LMWH. Arch Intern Med 1998;158:873-8.
27. Douketis J, Eikelboom J, Ouinlan D, Crowther M. The epidemiology of venous thromboembolism after hip and knee arthroplasty. Thromb Haemost 2001;Suppl(CD):abstract P2213.
28. Caprini JA, Arcelus JI, Motykie G, Kudma JC, Mokhtee D, Reyna JJ. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vasc Surg 1999;30:813-20.
29. Dahl OE, Pleil AM. Interpreting data from clinical studies of thromboprophylaxis. When is an event not an event? Thromb Haemost 2001;Suppl(CD):abstract P2260.
30. Ascani A, Radicchia S, Parise P, Nenci GG, Agnelli G. Distribution and occlusiveness of thrombi in patients with surveillance detected deep vein thrombosis after hip surgery. Thromb Haemost 1996;75:239-41.
31. Verlato F, Bruchi O, Prandoni P, Camporese G, Maso G, Busonera F, et al. The value of ultrasound screening for proximalvein thrombosis after total hip arthroplasty. A prospective cohort study. Thromb Haemost 2001;Suppl(CD):abstract P700.
32. Detoumay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of LMWH in prolonged prophylaxis against deep vein thrombosis after total hip replacement in France. Pharmacoeconomics 1998;13(1):81-9.
33. Bergqvist D, Jöhnsson B. Cost-effectiveness of prolonged administration of LMWH for the prevention of deep venous thrombosis following total hip replacement in Sweden. Value in Health 1999;2:288-94.